The Loss of miR-26a-Mediated Post-Transcriptional Regulation of Cyclin E2 in Pancreatic Cancer Cell Proliferation and Decreased Patient Survival

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Deng, Jingjing ^a   He, Miaoxia ^a   Chen, Lizao ^b   Chen, Chao ^b   Zheng, Jianming ^a   Cai, Zailong ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D2; CYCLIN E; CYCLIN E2; CYCLINE; MICRORNA 26A; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BENIGN TUMOR; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENICITY; CELL ASSAY; CELL CYCLE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STRAIN CAPAN 2; CELL STRAIN PANC 1; CELL STRAIN SW 1990; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; EPITHELIUM CELL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR XENOGRAFT; VALIDATION PROCESS; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MIDDLE AGED; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TISSUE ARRAY ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN;

EID: 84885123899     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076450     Document Type: Article

References (33)

1. Hayat MJ, Howlader N, Reichman ME, Edwards BK, (2007) Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12(1): 20-37.
2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, et al. (2003) Cancer statistics, 2003. CA Cancer J Clin 53(1): 5-26.
3. Delpu Y, Hanoun N, Lulka H, Sicard F, Selves J, et al. (2011) Genetic and epigenetic alterations in pancreatic carcinogenesis. Curr Genomics 12(1): 15-24.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J. Clin 59(4): 225-249.
5. Bartel DP, (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2): 281-297.
6. Croce CM, Calin GA, (2005) miRNAs, cancer, and stem cell division. Cell 122(1): 6-7.
7. Wang J, Sen S, (2011) MicroRNA functional network in pancreatic cancer: from biology to biomarkers of disease. J Biosci 36(3): 481-91.
8. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M, (2008) MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg 12(12): 2171-6.
9. Ryu JK, Matthaei H, Dal Molin M, Hong SM, Canto MI, et al. (2011) Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma. Pancreatology 11(3): 343-50.
10. Ji J, Shi J, Budhu A, Yu Z, Forgues M, et al. (2009) MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361(15): 1437-47.
11. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, et al. (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137(6): 1065-17.
12. Chen L, Zheng J, Zhang Y, Yang L, Wang J, et al. (2011) Tumor-specific expression of microRNA-26a suppresses human hepatocellular carcinoma growth via cyclin-dependent and-independent pathways. Mol Ther 19(8): 1521-8.
13. Bosman FT, Cameiro F, Hruban RH, Theise ND (2010) World Health Organization Classification of Tumours of the Digestive System. IARC: Lyon.
14. Sahin F, Maitra A, Argani P, Sato N, Maehara N, et al. (2003) Loss of Stk11/Lkb1 expression in pancreatic and biliary neoplasms. Mod Pathol 16(7): 686-91.
15. Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, et al. (2007) Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 67(24): 11612-20.
16. Jørgensen S, Baker A, Møller S, Nielsen BS, (2010) Robust one-day in situ hybridization protocol for detection of microRNAs in paraffin samples using LNA probes. Methods 52(4): 375-81.
17. Moelans CB, Milne AN, Morsink FH, Offerhaus GJ, van Diest PJ, (2011) Low frequency of HER2 amplification and overexpression in early onset gastric cancer. Cell Oncol (Dordr) 34(2): 89-95.
18. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods 25(4): 402-8.
19. Rachagani S, Kumar S, Batra SK, (2010) MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications. Cancer Lett 292(1): 8-16.
20. Avan A, Crea F, Paolicchi E, Funel N, Galvani E, et al. (2012) Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther 11: 1735-1746.
21. Chen S, Zheng J, Hao Q, Yang S, Wang J, et al. (2010) p53-insensitive PUMA down-regulation is essential in the early phase of liver regeneration after partial hepatectomy in mice. J Hepatol 52(6): 864-71.
22. Calin GA, Croce CM, (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6(11): 857-66.
23. Esquela-Kerscher A, Slack FJ, (2006) Incomes-microRNAs with a role in cancer. Nat Rev Cancer 6(4): 259-69.
24. Calin GA, (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101(9): 2999-3004.
25. Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, et al. (2009) The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 23(11): 1327-37.
26. Kim H, Huang W, Jiang X, Pennicooke B, Park PJ, et al. (2010) Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc Natl Acad Sci USA 107(5): 2183-8.
27. Zhou J, Ju W, Wang D, Wu L, Zhu X, et al. (2012) Down-regulation of microRNA-26a promotes mouse hepatocyte proliferation during liver regeneration. PLoS One 7(4): e33577.
28. Zhang B, Liu XX, He JR, Zhou CX, Guo M, et al. (2011) Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis 32(1): 2-9.
29. Lu J, He ML, Wang L, Chen Y, Liu X, et al. (2011) MiR-26a Inhibits Cell Growth and Tumorigenesis of Nasopharyngeal Carcinoma through Repression of EZH2. Cancer Res 71(1): 225-233.
30. Sander S, Bullinger L, Wirth T, (2009) Repressing the repressor: a new mode of MYC action in lymphomagenesis. Cell Cycle 8(4): 556-9.
31. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, et al. (2004) Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64(11): 3753-6.
32. Ikenaga N, Ohuchida K, Mizumoto K, Yu J, Kayashima T, et al. (2010) MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann Surg Oncol 17(12): 3120-8.
33. Heinzelmann J, Henning B, Sanjmyatav J, Posorski N, Steiner T, et al. (2011) Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol 29(3): 367-73.